RECURRENT EPENDYMOMA
Clinical trials for RECURRENT EPENDYMOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT EPENDYMOMA trials appear
Sign up with your email to follow new studies for RECURRENT EPENDYMOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug ivosidenib tested in kids with rare, returning cancers
Disease control OngoingThis phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare cancers: targeted drug larotrectinib tested in small trial
Disease control OngoingThis phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New radioactive antibody treatment shows promise for childhood brain cancer
Disease control OngoingThis Phase 2 trial tests a new approach for children whose medulloblastoma or ependymoma has come back. It combines a radioactive antibody (omburtamab) delivered directly into the brain's fluid spaces with standard chemotherapy drugs. The goal is to see if this combination can he…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising brain tumor treatment study halted before it began
Disease control TerminatedThis study aimed to test a new way to treat brain tumors that came back after standard therapy. The plan was to deliver immunotherapy (nivolumab) plus chemotherapy directly into the fluid spaces of the brain in children and adults. However, the study was withdrawn before any part…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE1 • Sponsor: Jeffrey Treiber • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Matched conditions: RECURRENT EPENDYMOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC